Holen Sie sich die Stockscreener-App
22.32
2.96%
-0.68
Vorhandelsmarkt:
22.39
0.07
+0.31%
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Alumis Stock Sinks As Revenue Shock Jolts Hopes - TipRanks
ALMS Q1 2026 Earnings: EPS Beat Drives 15.55% Stock SurgeRevenue Warning Signal - newsline.com
Alumis Shares Surge 16% as Traders Eye New Drug Move - TechStock²
Why Alumis Inc. Shares Are Suddenly Climbing - TipRanks
ALMS Q1 2026 Earnings: Narrower-Than-Expected Loss Propels Stock HigherMargin Compression Risk - newsline.com
Alumis | SCHEDULE 13D/A: Others - Moomoo
ACT CAPITAL MANAGEMENT, LLC's Alumis Inc(ALMS) Holding History - GuruFocus
ALMS Stock Chart | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Why Alumis Inc. Stock Is Sinking So Sharply - TipRanks
ALMS Q1 2026 Earnings: EPS Surprises to the Upside Amid Pre-Revenue Clinical StagePre-Earnings Drift - newsline.com
Has Alumis's Envudeucitinib Redefined Psoriasis Treatment - Kavout
Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements - Insider Monkey
Alumis Inc. (ALMS) Edges Higher: Modest Gains Amid Key Support and Resistance LevelsHedge Fund Exposure - newsline.com
ALMS Q1 2026 Earnings: EPS Beat Partially Offsets Investor ConcernsProfit Cycle Analysis - The Legal Advocate
Alumis (ALMS) Chief Medical Officer exercises stock options for 26,852 shares - Stock Titan
10 Under-the-Radar Stocks with Massive Upside for 2026 - Insider Monkey
TOWERVIEW LLC's Alumis Inc(ALMS) Holding History - GuruFocus
Alumis Inc. promotes investigational TYK2 inhibitor envudeucitinib at clinical dermatology congress - Traders Union
Alumis Inc. (ALMS) Q1 2026 Earnings: Narrower Loss Mirrors Operational Discipline, Pre-Revenue Stage PersistsEPS Guidance Update - The Legal Advocate
Alumis Inc. (ALMS) Edges Lower, Consolidating Above Key Support LevelWyckoff Distribution - newsline.com
How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors - simplywall.st
Alumis | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers - Moomoo
Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS - Benzinga
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model? - Yahoo Finance
ALMS Maintained by Chardan Capital -- Price Target Raised to $40 - GuruFocus
Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Alumis price target raised to $40 from $38 at Chardan - TipRanks
Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating - marketscreener.com
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones - Sahm
This Alumis analyst is no longer bullish; here are top 5 downgrades for Friday - MSN
ALUMIS INC. ($ALMS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] ALUMIS INC. SEC Filing - Stock Titan
[DEF 14A] ALUMIS INC. Definitive Proxy Statement - Stock Titan
Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026 - IndexBox
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors? - Sahm
Alumis’ Envudeucitinib Hits 68% PASI 90 in Phase 3 Psoriasis Trial - The Clinical Trial Vanguard
HC Wainwright & Co. downgrades Alumis (ALMS) - MSN
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back - AOL.com
A Quick Look at Today's Ratings for Alumis(ALMS.US), With a Forecast Between $25 to $55 - Moomoo
All News about Alumis Inc.Common Stock - The Chronicle-Journal
ALMS Maintained by Guggenheim -- Price Target Raised to $34 - GuruFocus
ALMS Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin asset - Endpoints News
Stifel reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Stifel reiterates Alumis stock rating on psoriasis trial data - Investing.com
Why Alumis Inc. Stock Is Sliding After Good News - TipRanks
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
H.C. Wainwright Downgrades Alumis(ALMS.US) to Hold Rating, Maintains Target Price $25 - Moomoo
Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $51 - Moomoo
Guggenheim raises Alumis stock price target to $34 on psoriasis data - Investing.com Nigeria
Guggenheim raises Alumis stock price target to $34 on psoriasis data By Investing.com - Investing.com South Africa
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):